Replies to post #174143 on Innovation Pharmaceuticals Inc (IPIX)

[runninggirl2016]

OM trial started 5/26/2015.
4 sites originally recruiting
12 sites currently recruiting. 1 waiting to start up.
6 were added in the last 12 months.
36 patient have already been enrolled. That's 60% completion.
Do the math...


Spin these trials how ever you want but the Facts are:

P P2b WILL BE DONE THIS YEAR
B-OM P2 WILL BE DONE THIS YEAR
B-UP P2a WILL BE DONE THIS YEAR
K-OC P2a WILL BE DONE THIS YEAR
S-HORTS WILL BE DONE THIS YEAR

[sox040713]

How would you know this?

Mar'17 - not heard about interim results - so 36 patients not yet recruited

From the 1/4/2017 PR,

"In advance of interim data collection and analyses planned for 1Q2017 to early 2Q2017 for the ongoing Phase 2 trial for Brilacidin-OM, Cellceutix would like to provide additional insight into this mid-phase study."

http://www.cellceutix.com/press-release/2017/1/4/cellceutix-to-present-at-biotech-showcase-2017-brilacidin-for-oral-mucositis-nears-interim-results

That tells me 36 patients have been enrolled at the time of the PR because the total time frame is 11 weeks (7 weeks treatment + 4 weeks follow-up).

[djs7]

Brilacidin OM interim analysis is 6-8 weeks from Feb 16, 2017:

February 16, 2017
Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones
Corporate
BEVERLY, MA – February 16, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB: CTIX) (“the Company”),

Brilacidin—Oral Mucositis (Phase 2 Trial)
o Enrolling 60 patients, the study is evaluating Brilacidin as an oral rinse, 3 times daily for 7 weeks, to prevent and control Oral Mucositis (OM) in patients receiving chemoradiation therapy for head and neck cancer. Even though over 400,000 patients in the U.S. suffer from this condition, presently there are no approved drugs for the treatment of OM in this population, with only limited palliative care options available. Cellceutix’s goal with this trial is to show that Brilacidin has dual functionality in not only shortening the duration and intensity of OM in patients with head and neck cancers, but also preventing the onset of the condition, an accomplishment no other pharmaceutical company has achieved.

o Upcoming Milestone: Interim analysis of the Phase 2 trial is expected in approximately 6 to 8 weeks.


PR Reference for release of Brilacidin OM interim ananlysis:
http://www.cellceutix.com/press-release/2017/2/15/y3616250ilexnq8enkoy8lelciljue

Mar'17 - not heard about interim results - so 36 patients not yet recruited